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Context: Results from animal studies suggest that consumption of large amounts of fructose can
promote inflammationand impair fibrinolysis.Datadescribing theeffects of fructose consumption
on circulating levels of proinflammatory and prothrombotic markers in humans are unavailable.
Objective: Our objective was to determine the effects of 10 wk of dietary fructose or glucose con-
sumption on plasma concentrations of monocyte chemoattractant protein-1 (MCP-1), plasminogen
activator inhibitor-1 (PAI-1), E-selectin, intercellular adhesionmolecule-1, C-reactive protein, and IL-6.
Design and Setting: This was a parallel-arm study with two inpatient phases (2 wk baseline, final
2 wk intervention), conducted in a clinical research facility, and an outpatient phase (8 wk) during
which subjects resided at home.
Participants: Participants were older (40–72 yr), overweight/obese (body mass index 25–35 kg/m2)
men (n 16) and women (n 15).
Interventions:Participants consumedglucose-or fructose-sweetenedbeveragesproviding25%ofenergy
requirementsfor10wk.Bloodsampleswerecollectedatbaselineandduringthe10thweekofintervention.
Main Outcome Measures: Fasting concentrations of MCP-1 (P  0.009), PAI-1 (P  0.002), and
E-selectin (P  0.048) as well as postprandial concentrations of PAI-1 (P  0.0001) increased in
subjects consuming fructose but not in those consuming glucose. Fasting levels of C-reactive pro-
tein, IL-6, and intercellular adhesion molecule-1 were not changed in either group.
Conclusions:Consumptionoffructosefor10wkleadstoincreasesofMCP-1,PAI-1,andE-selectin.These
findings suggest the possibility that fructose may contribute to the development of the metabolic
syndrome via effects on proinflammatory and prothrombotic mediators. (J Clin EndocrinolMetab 96:
E2034–E2038, 2011)
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We recently reported that consumption of fructose-sweetened beverages for 10 wk, at 25% of energy
requirements, promotes the development of three patho-
logical characteristics associated with metabolic syn-
drome: dyslipidemia, decreased insulin sensitivity, and
increased visceral adiposity in older, overweight adults
compared with isocaloric consumption of glucose (1).
Metabolic syndrome has also been shown to be associated
with proinflammatory and prothrombotic conditions,
and there is considerable evidence supporting a relation-
ship between components of the metabolic syndrome and
plasma concentrations of biological markers of inflam-
mation and thrombosis (2).
To determine whether fructose-induced dyslipidemia,
increases of visceral adiposity, and reductions of insulin
sensitivity are accompanied by an increase of systemic in-
flammation and/or impaired fibrinolysis, we measured
circulating concentrations of monocyte chemoattractant
protein-1 (MCP-1), plasminogen activator inhibitor-1
(PAI-1), soluble leukocyte adhesion molecule-1 (E-selec-
tin), soluble intercellular adhesion molecule-1 (ICAM),
C-reactive protein (CRP) and IL-6 at baseline and after 10
wk of intervention in the subjects from our previous in-
vestigation (1). The results indicate that consumption of
fructose, but not glucose, at 25% of energy requirements
increases plasma concentrations of MCP-1, E-selectin,
and PAI-1. Circulating concentrations of CRP, IL-6, and
ICAM were unchanged during consumption of either
sugar.
Subjects and Methods
Study design
This was a parallel-arm study with three phases: 1) a 2-wk
inpatient baseline period, 2) an 8-wk outpatient intervention
period, and 3) a 2-wk inpatient intervention period. During the
baseline and inpatient intervention periods, subjects resided in
the University of California-Davis Clinical and Translational
Science Center’s Clinical Research Center, and during the 8-wk
outpatient intervention, subjects resided at home. During the
intervention phases, subjects consumed either fructose-sweet-
ened (n 16) or glucose-sweetened (n 15) beverages at 25%
of energy requirements.
Subjects
Inclusion criteria included age 40–72 yr and bodymass index
(BMI) of 25–35 kg/m2 with a self-report of stable body weight
during the previous 6months.Womenwere categorized as post-
menopausal based on self-reports of nomenstruation for at least
1 yr. Exclusion criteria included evidence of diabetes, renal or
hepatic disease, fasting serum triglyceride (TG) concentrations
over 400 mg/dl, hypertension, and weight loss surgery. Individ-
uals who smoked, exercised more than 3.5 h/wk at a level more
vigorous than walking, or used thyroid, lipid-lowering, glucose-
lowering, antihypertensive, antidepressant, or weight-loss med-
ications were also excluded. The University of California-Davis
Institutional ReviewBoard approved the experimental protocol.
Subjects provided informed consent to participate in the study.
Thirty-nine subjects enrolled in the study, and experimental
groups were matched for gender, BMI, and fasting TG and in-
sulin concentrations. As reported by Stanhope et al. (1), baseline
anthropomorphic and metabolic characteristics did not differ
between the two experimental groups. Seven subjects did not
complete the study because of inability or unwillingness to com-
ply with protocol or due to personal or work-related conflicts.
Wewere unable tomeasure inflammatorymarkers in one female
subject in the fructose group due to a lack of plasma samples.
Subjectswere primarily Caucasian (n 24); however,Hispanics
(n 5) and African-Americans (n 3) were also included in the
study.
Diets
During inpatient metabolic phases, subjects consumed diets
designed to maintain energy balance (15% of energy as protein,
30% as fat, and 55% as carbohydrate). Daily energy intake was
calculated at baseline using theMifflin equation to estimate rest-
ing energy expenditure and adjusted for activity using a multi-
plication factor (1.3–1.5). During baseline, the carbohydrate
content consisted primarily of complex carbohydrates. For the
final 2-wk inpatient interventionperiod, subjects consumeddiets
at baseline energy levels and macronutrient composition except
that 30% of energy was from complex carbohydrates and 25%
was provided by fructose- or glucose-sweetened beverages. Ad-
ditional details about dietary composition and intake have been
described previously (1).
Fasting and postprandial blood samples
The 24-h blood collections were conducted during baseline
and after 10 wk of intervention. Three fasting blood samples
were collected at 0800, 0830, and 0900 h. Thirty-three post-
prandial blood samples were collected at 30- to 60-min intervals
from 0930 until 0800 h the nextmorning. Plasma from the three
fasting samples (0800, 0830, and 0900 h) was pooled, as was
plasma from the final three postprandial blood samples of the
day (2200, 2300, and 2330 h); multiple aliquots of each pooled
sample were stored at 80 C.
Measurement of inflammatory markers
MCP-1, PAI-1, ICAM, and IL-6 (high sensitivity) were quan-
tified using commercially available ELISA kits from R&D Sys-
tems (Minneapolis, MN), E-selectin was measured using an
ELISA from Bender Medsystems/eBioscience (San Diego, CA),
and CRP levels were determined using a Polychem Chemistry
Analyzer (PolyMedCo, Inc., Cortlandt Manor, NY).
Data analysis
Statistical tests were performed with SAS version 9.2. The
absolute or percent change for each outcome was calculated for
each subject, and these values were averaged for the two groups
and then analyzed in a two-factor (type of sugar and gender)
mixed procedures (PROCMIXED)ANOVAmodelwith adjust-
ment for differences in baseline values. Variability in responses
between individuals accounts for the differences between the
average changes calculated on a per-subject basis and the ap-
parent changes based on the means for each group. Outcomes
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with least-squares means of the change (10 vs. 0 wk) signifi-
cantly different from zerowere identified. Statistical tests with
P values 0.05 were considered significant. Data are pre-
sented as mean  SEM. Data were also adjusted for age and
ethnicity in a separate analysis (Supplemental Table 1, pub-
lished on The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org).
Results
MCP-1
Fasting plasma concentrations of MCP-1 were not sig-
nificantly changed from baseline in subjects consuming
glucose-sweetened beverages (P 0.634) (Table 1).How-
ever, in subjects consuming fructose, MCP-1 levels in-
creased significantly compared with baseline values (P 
0.0009) and compared with subjects in the glucose group
(P  0.03 for effect of sugar) (Table 1).
PAI-1
Fasting plasma PAI-1 concentrations increased signif-
icantly from baseline in subjects consuming fructose (P
0.002) but not in those consuming glucose (P0.53) (P
0.07 for effect of sugar) (Fig. 1). As with fasting PAI-1
levels, postprandial plasmaPAI-1 levels also increased sig-
nificantly in the fructose group, both comparedwith base-
line (1.760.39ng/ml;P0.0001) and comparedwith
subjects consuming glucose (P 0.03 for effect of sugar)
(Table 1). Postprandial PAI-1 levels were unchanged in
subjects consuming glucose. (0.57  0.28 ng/ml; P 
0.06) (Table 1).
E-selectin and ICAM
Fasting plasma concentrations of E-selectin were sig-
nificantly increased from baseline in subjects consuming
fructose-sweetened beverages (P 0.048) but not in sub-
jects consuming glucose-sweetened beverages (P 0.95);
however, the difference in response between the groups
did not reach significance (P  0.17 for effect of sugar)
(Table 1). Although fasting plasma ICAM levels tended to
increase slightly in subjects consuming fructose and re-
main unchanged in subjects consuming glucose, the re-
sponses were not statistically significant (Table 1).
CRP and IL-6
Fasting plasma concentrations ofCRPwere unchanged
in subjects consuming fructose (0.63  0.48 mg/liter;
P  0.75) or glucose (1.32  1.16 mg/liter; P  0.29)
(P0.33 for effectof sugar) (Table1).Thehighvariability
of CRP responses (75% of mean) led to discrepancies
between the absolute and percent changes calculated, par-
ticularly for the glucose group (Table 1). Fasting plasma
concentrations of IL-6 were not changed in either exper-
imental diet group (Table 1).
FIG. 1. Fasting concentrations of PAI-1 (nanograms per milliliter)
before and after 10 wk of consuming fructose- or glucose-sweetened
beverages. **, P  0.01 compared with baseline values using PROC
mixed two-factor (sugar and gender) ANOVA with adjustment for
differences in baseline values; P  0.07 for effect of sugar. Fructose
group, n  16; glucose group, n  15.
TABLE 1. Fasting plasma concentrations of MCP-1, E-selectin, ICAM, IL-6, and CRP and postprandial
concentrations of PAI-1 at baseline and after 10 wk of consumption of fructose- or glucose-sweetened beverages
Fructose Glucose
P value for
effect of sugarBaseline 10 wk
% change
at 10 wk Baseline 10 wk
% change
at 10 wk
MCP-1 (pg/ml) 144.7  18.8 199.3  19.4 83.5  32.9c 178.7  10.5 163.2  18.3 9.2  9.9 0.03
ppPAI-1 (ng/ml) 3.8  0.5 4.6  0.5 48.5  16.4c 5.2  0.9 5.0  0.7 1.6  7.8 0.03
E-selectin (ng/dl) 45.0  5.5 51.5  4.6 29.3  13.7b 50.0  5.5 49.2  4.6 5.9  8.2 0.17
ICAM (ng/ml) 221.9  6.3 228.4  6.9 3.5  2.8 190.1  21.8 188.2  22.0 0.5  3.2 0.22
IL-6 (pg/ml) 3.5  0.7 3.1  0.5 7.2  11.9 3.3  0.7 3.9  1.0 20.3  15.8 0.31
CRPa (mg/liter) 3.7  0.8 3.1  0.6 5.0  9.2 5.7  2.4 4.4  1.3 11.1  18.1 0.33
Values are means  SEM; n  31 (fructose group n  16; glucose group n  15). PROC MIXED two-factor (sugar and gender) ANOVA with
adjustment for differences in baseline values was used. ppPAI-1, Postprandial PAI-1.
a P values reported are for absolute change rather than percent change due to the high variability in CRP responses (see Supplemental Fig. 1 for
individual responses for all variables).
b,c Changes significantly different from baseline: b P  0.05; c P  0.001.
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Discussion
MCP-1 and PAI-1
In humans, visceral adipose mass has been shown to be
a primary determinant of PAI-1 levels (3), and both PAI-1
(4) andMCP-1 (5) have been shown to be preferentially
secreted from visceral adipose tissue compared with sc
adipose tissue. Thus, it is possible that the increased
deposition of visceral adipose tissue in subjects con-
suming fructose may help to explain the observed in-
creases of PAI-1 andMCP-1 in subjects consuming fruc-
tose; however, we did not detect any significant
correlations between increases of VAT and increases of
MCP-1 and PAI-1 (1).
Elevated levels of TG-rich lipoproteins have also been
shown to be associated with increased PAI-1 concentra-
tions (6). Moreover, it has been demonstrated that very-
low-density lipoprotein-derived TG particles can induce
PAI-1 expression in vascular endothelial cells (7). Consid-
ering that levels of TG-rich lipoproteins are measurably
higher postprandially and that the increases of lipids and
lipoproteins exhibited by subjects consuming fructose
were also more pronounced during the postprandial state
(1), we hypothesized that increases of PAI-1would also be
greater in the postprandial state. Although the difference
between fasting andpostprandial PAI-1 responseswas not
statistically significant, the absolute increase in postpran-
dial PAI-1 levels was more than twice as large as the in-
crease of fasting levels (see Results and Fig. 1).
It has been suggested that activation of protein kinase
C (PKC) is responsible for the increased levels of PAI-1
observed in insulin resistance (8). PKC also appears to be
involved in the stimulation of MCP-1 production, and
secretion of MCP-1 from human liver fat-storing cells
(stellate cells) is dependent onPKCactivation (9).Wehave
suggested that the reductions of insulin sensitivity and glu-
cose tolerance previously reported in the subjects fromour
study were primarily the result of fructose-induced in-
creases of hepatic de novo lipogenesis leading to accumu-
lation of hepatic lipid and subsequent diacylglycerol-me-
diated PKC activation (1, 10, 11). The evidence linking
expression of MCP-1 and PAI-1 to PKC activation sug-
gests the possibility that the increases ofMCP-1 andPAI-1
exhibited in response to fructose consumptionmayalso be
mediated by this mechanism, although we acknowledge
that evidence for thismechanism is speculative becausewe
were unable to obtain liver biopsies to measure PKC
activity.
Cellular adhesion molecules, IL-6, and CRP
It is interesting that prolonged fructose consumption
led to significant increases of E-selectin but not ICAM.
Although there is evidence supporting a relationship be-
tween indices of insulin resistance and increased concen-
trations of various cellular adhesion molecules, several
studies have reported that levels of E-selectin and/or
ICAM are correlated with visceral fat volume (12) and
reduced insulin sensitivity (13). The reductions of insulin
sensitivity and increases of visceral adiposity that we have
reported previously in these same subjects (1), together
with the selective increase of E-selectin, support the rela-
tionships identified in previous investigations.
There is a growing body of evidence that the inflam-
matory mediators CRP and IL-6 are associated with
proatherogenic conditions (14). Therefore, it is interesting
that concentrations of CRP and IL-6 were unaffected by
prolonged fructose consumption, despite other proin-
flammatory changes. These findings suggest that fruc-
tose consumption has a pleiotropic effect on markers of
inflammation such that certain mediators are preferen-
tially up-regulated (MCP-1, PAI-1, and E-selectin),
whereas others (IL-6 and CRP) are not.
Conclusions
Consumption of fructose at 25% of energy require-
ments for 10 wk leads to increases of fasting MCP-1,
PAI-1, andE-selectin aswell as postprandial PAI-1 but not
IL-6, CRP, or ICAMconcentrations. These results suggest
the possibility that prolonged consumption of fructose
maycontribute to thedevelopmentofmetabolic syndrome
via induction of specific proinflammatory (MCP-1 and
E-selectin) and prothrombotic (PAI-1) mediators. Addi-
tional studies examining larger groups of subjects are
needed to confirm these findings.
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